CareFusion — Q4 FY2014 Earnings Presentation
34 slides from CareFusion's earnings presentation, Nov 19, 2014
Slide 1: Fourth Quarter and Full-Year Results Fiscal Year 2014, Fiscal Year 2015 Guidance
Fourth Quarter and Full-Year Results Fiscal Year 2014 Fiscal Year 2015 Guidance November 4, 2014
Slide 2: Forward-Looking Statements, Non-GAAP Financial Measures
Forward-Looking Statements Non-GAAP Financial Measures Results from Continuing Operations FXN = Estimated foreign exchange-neutral currency growth. $ = Dollars in millions except per share data. Note: All figures on accompanying slides are rounded. Totals may not add due to rounding. Percentages are
Slide 3: Our Strategy Continued to Deliver Results
Our Strategy Continued to Deliver Results 2014 Key Achievements: Strong revenue growth of 5.2% Launched an array of new products bringing new products as a percentage of sales to 15% Emerging Market investments continue to fuel growth Operating effectiveness and efficiency initiatives continued to d
Slide 4: FY 2015 Guidance Overview
FY 2015 Guidance Overview FY 2014 FY 2014 “Cash” EPS 1 FY 2015 Guidance 4.5% to 5% $6.76 to $6.83 8% to 9% Beginning in fiscal year 2015, adjusted EPS will exclude the amortization of acquisition-related intangibles, net of tax. Revenues (FXN) Adjusted EPS $ $6.25 $6.50 Adjusted EPS Growth (FXN)
Slide 5: Q4 FY 2014 Highlights
Q4 FY 2014 Highlights Strong revenue growth of 5.2% Revenue growth of 4.6% FXN, driven by Medical and Diagnostics Bioscience growth impacted by an unfavorable comparison to the prior year, as expected Emerging markets and international safety sales continue to drive robust growth Continued tax rate
Slide 6: FY 2014 Revenues by Segment
FY 2014 Revenues by Segment Fourth Quarter Total Year $ Reported Growth % FXN Growth% $ Reported Growth % FXN Growth% Total Revenues $2,202 4.8% 4.6% $8,446 4.9% 5.2% Medical 1,193 4,573 Diagnostics 2,713 Biosciences 1,159
Slide 7: FY 2014 U.S. and International Revenues
FY 2014 U.S. and International Revenues Fourth Quarter Total Year $ Reported Growth % FXN Growth% $ Reported Growth % FXN Growth% U.S. $871 2.3% 2.3% $3,417 1.9% 1.9% International $1,331 6.6% 6.2% $5,029 7.0% 7.6% Medical 1,799 Diagnostics 1,251 -1.7% -1.7% Biosciences Medical 2,774 Diagnostics 1,4
Slide 8: Emerging Markets
Emerging Markets FXN Growth % % of BD Revenues Note: Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and Asia Pacific (excluding Japan) Emerging Markets financial highlights for FY 2014: Fourth quarter growth in key markets and platforms (FXN) China Emerging Markets Safe
Slide 9: FY 2014 Safety Revenues
FY 2014 Safety Revenues Fourth Quarter Total Year $ Reported Growth % FXN Growth% $ Reported Growth % FXN Growth% Total Safety $566 5.7% 5.5% $2,223 5.9% 6.6% By Geography U.S. -0.8% -0.8% 1,207 International 1,016 By Segment Medical 1,119 Diagnostics 1,104
Slide 10: Q4 FY 2014 Adjusted Gross Margin
51.9% 51.0% Performance 0.8% 0.1% % of Revenue Q4 FY 2014 Adjusted Gross Margin Change Year-Over-Year -0.9% ReLoCo, Continuous Improvement, Pension +60 bps Mix, Price, Start-up Costs, Raw Materials -70 bps 50% 51% 52% Q4 FY2013 Currency Performance Q4 FY 2014 $1,089 $1,123
Slide 11: Q4 FY 2014 Income Statement
Q4 FY 2014 Income Statement Favorable (Unfavorable) Adjusted Q4 FY 2014 Adjusted Q4 FY 2013 $ Change % Change FXN % Change EPS $1.68 $1.54 $0.14 9.1% 13.0% Revenues $2,202 $2,101 Gross Profit 1,123 1,089 % of Revenues SSG&A (9) -1.7% -1.3% % of Revenues R&D (0) -0.3% -0.2% % of Revenues Operating In
Slide 12: FY 2015 Revenue Guidance
FY 2015 Revenue Guidance 2014 Actual November Guidance Total BD Revenues 5.2% 4.5% to 5.0% Growth % (FXN) Medical 4.5% to 5.0% Life Sciences ~ 4.5% Diagnostics ~ 4.0% to 4.5% Biosciences ~4.5% to 5.0%
Slide 13: FY15 Adjusted EPS Guidance
FY15 Adjusted EPS Guidance $6.76 to $6.83 FY 2015 share repurchase program has been suspended due to the pending CareFusion acquisition. Estimates are based on what the impact of a $450 repurchase program could have on diluted earnings per share. Estimated EPS impact is ~1 percent, or $0.07 to $0.09
Slide 14: FY 2015 Guidance
FY 2015 Guidance Adjusted FY 2014 Adjusted FY 2014 1 for “Cash” EPS FY 2015 1,2 Guidance ~52% ~25% ~6% 20.5% to 21.0% 21.5% to 22.5% $6.76 to $6.83 8.0% to 9.0% ~$1.85B EPS headwind of ~1%, or ($0.07) to ($0.09) ~$625M Gross Profit SSG&A R&D Operating Income Effective Tax Rate EPS $6.25 $6.50 EPS –
Slide 15: FY 2014 in Review: Program and Product Launch Updates
FY 2014 in Review Program and Product Launch Updates New New New Medical Program/Product Launch Date BD Simplist ™ Prefilled Injectables Morphine Sulfate Injection, USP Launched Midazolam Injection, USP Approved Biosciences Program/Product Launch Date BD FACSPresto ™ Launched BD OneFlow ™ Solution -
Slide 16: FY 2014 in Review: Program and Product Launch Updates
FY 2014 in Review Program and Product Launch Updates Diagnostics Program/Product Launch Date BD Veritor ™ System Strep A, RSV Launched WW BD MAX ™ Staph SR, MRSA XT Launched WW Enteric Bacteria Launched WW Enteric Parasite Launched EU BD Totalys ™ Launched EU BD Viper ™ LT BD Onclarity ™ HPV-GT Laun
Slide 17: New Program and Product Launch Updates
New Program and Product Launch Updates Medical Program/Product Planned Launch Date BD Insulin Infusion Sets FY 2015 FDA Clearance Expected BD Simplist ™ Prefilled Injectables Heparin Sodium Injection, USP FY 2016 Hydromorphone Hydrochloride Injection, USP FY 2016 Biosciences Program/Product Planned
Slide 18: New Program and Product Launch Updates
New Program and Product Launch Updates Diagnostics Program/Product Planned Launch Date BD MAX ™ Enteric Parasite Launched EU / Q3 FY 2015 U.S. (1 Q Delay) GC/CT and GC/CT/Trich Q3 FY 2015 EU Extended Enteric Bacterial Late FY 2015 / Early FY 2016 EU Enteric Viral Late FY 2015 / Early FY 2016 EU Vagi
Slide 19: Key Takeaways
Key Takeaways Pleased with our strong fiscal year 2014 results Exceeded financial and operational goals Revenue growth of 5.2%, EPS growth of 11.4% Strong foundation for continued growth Continue to evolve into a customer focused provider of complete solutions Looking forward to fiscal year 2015 wit
Slide 20: Q & A
Q & A BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company.
Slide 21: FY 2014 Financial Highlights
FY 2014 Financial Highlights Fourth Quarter Total Year $ Growth % FXN Growth % $ Growth % FXN Growth % Revenues $2,202 $8,446 EPS $1.53 NM NM $5.99 Adjusted EPS $1.68 $6.25 Adjusted EPS Ex-MDT NM NM NM $6.29
Slide 22: Q4 FY 2014 Revenue Growth Year-Over-Year
Q4 FY 2014 Revenue Growth Year-Over-Year -0.7% $2,202 $2,101 4.8% -0.2% 1,700 1,800 1,900 2,000 2,100 2,200 2,300 Q4 FY 2013 Performance Currency Q4 FY 2014
Slide 23: Q4 FY 2014 Adjustment Reconciliation
Q4 FY 2014 Adjustment Reconciliation (Unaudited; Amounts in millions, except per share data) Pension Carrying Workforce Acquisition Program Reported Settlement Amount Reduction Related Termination Adjusted FY 2014 Charge (1) Adjustment (2) Charge (3) Items (4) Charge (5) FY 2014 REVENUES $ 2,202 - -
Slide 24: Q4 FY 2014 Reconciliation – FX Impact
Q4 FY 2014 Reconciliation – FX Impact (Unaudited; Amounts in millions, except per share data) Adjusted Adjusted Adjusted Growth Adjusted Growth Foreign Currency FXN FXN FY 2014 FY 2013 $ % Translation Change Growth REVENUES $ 2,202 $ 2,101 $ $ $ Gross Profit 1,123 1,089 (16) % of Revenues Selling an
Slide 25: Q4 FY 2014 Reconciliation of Non-GAAP Financial Measures
Q4 FY 2014 Reconciliation of Non-GAAP Financial Measures (Unaudited) Growth Foreign Currency Translation Foreign Currency Neutral Change Growth % Foreign Currency Neutral Growth % Reported Diluted Earnings per Share from Continuing Operations $ 1.53 $ 0.46 $ 1.07 $ (0.06) $ 1.13 NM NM Non-cash pensi
Slide 26: FY 2014 Reconciliation - FX Impact Emerging Markets and China
FY 2014 Reconciliation - FX Impact Emerging Markets and China (Unaudited; Amounts in millions) Reported FXN FX Impact Total Emerging Markets Revenues $ $ Total Emerging Markets Safety Revenues $ $ China Revenues $ $ -1.0% Reported FXN FX Impact Total Emerging Markets Revenues $ 2,123 $ 1,943 -3.0% A
Slide 27: FY 2014 Total Year Revenue Growth Year-Over-Year
FY 2014 Total Year Revenue Growth Year-Over-Year 4.9% 0.3% $8,054 $8,446 $ in Millions 7,000 7,400 7,800 8,200 Q4 FY 2013 Performance Currency Q4 FY 2014
Slide 28: FY 2014 Total Year Adjusted Gross Margin
FY 2014 Total Year Adjusted Gross Margin Change Year-Over-Year -0.6% 0.0% 51.8% 51.2% -0.6% $4,174 $4,322 $ in Millions 50% 51% 52% Q4 FY 2013 Currency Performance Q4 FY 2014 Performance: ReLoCo, Continuous Improvement, Pension +80 bps Mix, Start-up Costs, Raw Materials -80 bps
Slide 29: FY 2014 Total Year Adjustment Reconciliation
FY 2014 Total Year Adjustment Reconciliation (Unaudited; Amounts in millions, except per share data) Contract Program Pension Carrying Workforce Acquisition Amortization Adjusted Reported Asset Termination Gain on Termination Settlement Amount Reduction Related Adjusted of Acquired FY 2014 (10) FY 2
Slide 30: FY 2014 Total Year Reconciliation – FX Impact
FY 2014 Total Year Reconciliation – FX Impact (Unaudited; Amounts in millions, except per share data) Adjusted FY 2014 Adjusted FY 2013 Adjusted Growth Adjusted Growth Foreign Currency FXN FXN EPS EPS $ % Translation Change Growth REVENUES $ 8,446 $ 8,054 $ $ (29) $ Gross Profit 4,396 4,247 (69) % o
Slide 31: Total Year Reconciliation of Non-GAAP Financial Measures
Total Year Reconciliation of Non-GAAP Financial Measures (Unaudited) Growth Foreign Currency Translation Foreign Currency Neutral Change Growth % Foreign Currency Neutral Growth % Reported Diluted Earnings per Share from Continuing Operations $ 5.99 $ 4.67 $ 1.32 $ (0.22) $ 1.54 Write-off of capital
Slide 32: Q4 FY 2013 Adjustment Reconciliation
Q4 FY 2013 Adjustment Reconciliation (Unaudited; Amounts in millions, except per share data) Pension Reported Verdict Settlement Adjusted FY 2013 Charge (1) Charge (2) FY 2013 REVENUES $ 2,101 - - $ 2,101 Gross Profit 1,086 - $ 1,089 % of Revenues Selling and administrative $ (341) (3) % of Revenues
Slide 33: FY 2013 Total Year Adjustment Reconciliation
FY 2013 Total Year Adjustment Reconciliation (Unaudited; Amounts in millions, except per share data) Litigation Pension Amortization Adjusted Reported Settlement Verdict Settlement Adjusted of Acquired FY 2013 (5) FY 2013 Charge (1) Charge (2) Charge (3) FY 2013 Intangibles (4) for "Cash" EPS REVENU
Slide 34: FY 2015 Outlook Reconciliation
FY 2015 Outlook Reconciliation Reported Basis FX Impact FXN Basis Revenues - Full Year 2015 estimated growth 2.0% - 2.5% (2.5%) 4.5% - 5.0% Full Year Full Year % Increase (estimated) Reported Fully Diluted Earnings per Share from Continuing Operations $ 6.47 - 6.54 $ 5.99 NM Amortization of acquisit